| P148 | Viral based vaccine for personalized neoantigen-directed cancer therapies | Christian Ottensmeier, MD PhD FRCP; Natalia Savelyeva; Katy McKann; Chuan Wang; Jason Greenbaum; Finn C. Nielsen; Chantal Hoffmann; Huguette Schultz; Nathalie Silvestre; Jean-Baptiste jb. Marchand, pHD; Maud Brandely-Talbot, MD, PhD; Eric Quemeneur, PharmD, PhD; Kaidre Bendjama, .; Kaidre Bendjama, . | Bioinformatics; Biomarkers; Immune adjuvant; Neoantigens; T cell; Tumor antigens |
| P149 | A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies | Ana B. Blazquez, PhD; Alexander Rubinsteyn, PhD; Julia Kodysh, MSc; John Finnigan; Thomas U. Marron, MD PhD; Rachel L. Sabado, PhD; Marcia Meseck, MS, JD; Timothy O'Donnell; Jeffrey Hammerbacher, BA; Michael Donovan; John Holt; Millind Mahajan; John Mandeli, PhD; Krysztof Misiukiewicz; Eric Genden; Brett Miles, DDS MD; Hooman Khorasani; Peter Dottino; Hanna Irie; Amy Tiersten, MD; Elisa Port; Andrea Wolf, MD; Hearn J. Cho, MD, PhD; Ashutosh Tewari, MD; Samir Parekh, MD; Sujit Nair; Matthew D. Galsky, MD; William K. Oh, MD; Sacha Gnjatic, PhD; Eric Schadt; Philip Friedlander, MD PhD; Nina Bhardwaj, MD, PhD; Nina Bhardwaj, MD, PhD; | Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; T cell; Tumor antigens; Vaccine |
| P150 | A Phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission | Anna C. Pavlick, MD, MBA; Ana B. Blazquez, PhD; Marcia Meseck, MS, JD; Michael Donovan; Mireia Castillo-Martin; Tin Htwe Thin, Ph.D.; Rachel L. Sabado, PhD; John Mandeli, PhD; Sacha Gnjatic, PhD; Philip Friedlander, MD PhD; Nina Bhardwaj, MD, PhD | Clinical trial; Dendritic cell; Immune adjuvant; Immune monitoring; Solid tumors; T cell; TLR; Vaccine |
| P151 | Improving neoantigen identification for therapeutic and diagnostic use in immuno-oncology using mass spectrometry and machine learning | Sean M. Boyle, PhD; Eric Levy, PhD; Gabor Bartha; Jason Harris; Rena McClory; John S. West, MBA; Richard Chen | Immune monitoring; Neoantigens; Proteomics; Solid tumors; Tumor microenvironment |
| P152 | Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy for cancer treatment | Ying Xuan Chua, PhD; Antonia Susnjar; Jeremy Ho; Jessica R. Rhudy; Priya Jain, B.S.; Marco Folci; Andrea Ballerini; Shailbala Singh; Carly S. Filgueira, Ph.D.; Cassian Yee, MD; Brian Butler; Alessandro Grattoni | Antibody; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P153 | Vaccination with HSP70iQ435 DNA elicits a broad, functional antibody response that may contribute to tumor control of melanoma | Cormac Cosgrove, PhD; I Caroline Le Poole; Emilia Dellacecca; Steven W. Henning | Antibody; Autoimmunity; Dendritic cell; T cell; Vaccine |
| P154 | Empiric profiling of neoantigen-specific T cell responses in NSCLC patients with ATLAS™ reveals unexpected neoantigen and inhibitory antigen profiles | Kyle Ferber, PhD, BS; Michael O'Keeffe; Crystal Cabral, BS, MSc; Christopher Warren; Erick Donis; Mariya Croll, MS; James Loizeaux; Melissa W. Hayes, PhD; James Perry; Wendy Broom, PhD; Pamela Carroll; Jessica B. Flechtner, PhD; Jason R. Dobson, PhD, BS; | Antigen presenting cells; Dendritic cell; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor antigens |
| P155 | A DNA-based CSPG4 cancer vaccine designed by SynCon® technology is highly immunogenic and extends survival in a mouse model of melanoma | Bradley Garman, MS; Bradley Garman, MS; Jewell N. Walters, BS PhD; Elizabeth K. Duperret, BS, PhD; Aspen Trautz; Jaemi Chu; Jian Yan, BS PhD; Laurent M. Humeau, BS, MS, PhD; David B. Weiner, BS, MS, PhD | Angiogenesis; Checkpoint blockade; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P156 | Developing a cross-reactive heteroclitic peptide cancer vaccine targetting poorly immunogenic mutant calreticulin in myeloproliferative neoplasms | Mathieu Gigoux, PhD; Shannon Elf, Ph.D.; Michele Ciboddo; Roberta Zappasodi, PhD; Stephane Pourpe, M.Sc.; Nouran Abdelfattah, M.Sc.; Timothy A. Chan, MD, PhD; Omar Abdel-Wahab, M.D.; Ann Mullally, M.D.; Taha Merghoub, PhD; Jedd D. Wolchok, MD, PhD | Antigen presenting cells; Neoantigens; T cell; Tumor antigens; Vaccine |
| P157 | ISA101 and nivolumab for HPV-16+ Cancer: Updated clinical efficacy and immune correlates of response | Bonnie S. Glisson; Erminia Massarelli, MD, PhD, MS; William William, MD; Faye M. Johnson, MD, PhD; Renata Ferrarotto, MD; Ming Guo; Lei Feng; J Jack Lee; Hai Tran; Jaime Rodriguez-Canales, MD; Tomas Zecchini Barrese; Ignacio Wistuba, MD; Jing Wang; Sjoerd H. van der Burg, PhD; Kimal Rajapakshe, PhD; Cornelis J. Melief, MD, PhD; Michael A. Curran, PhD; | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P158 | IFN-α and 5’-Aza-2’-deoxycytidine enhance the anti-tumor efficacy of a dendritic-cell targeting MIP3α-Gp100-Trp2 DNA vaccine by affecting T-cell recruitment and tumor microenvironment gene expression | James Gordy, PhD; Richard Markham, BS MD | Chemokine; Cytokine; Dendritic cell; Gene expression; Immune adjuvant; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P159 | Correlation between response and HLA type in a randomized phase IIb trial of NeuVax + trastuzumab in HER2 low-expressing breast cancer patients to prevent recurrence | Annelies T. Hickeron; Guy T. Clifton, MD, FACS; Tommy Brown, MD; John W. Myers, III, MD; Jessica L. Campf, MD; Kaitlin Peace, MD; Jennifer K. Litton; Rashmi Murthy; Timothy J. Vreeland, BS MD; Diane F. Hale, MD; Garth S. Herbert, MD; Jason Lukas, MD/PhD; Nicholas J. Sarlis; Jarrod P. Holmes; Elizabeth A. Mittendorf; George E. Peoples, MD, FACS | Antigen presenting cells; Clinical trial; Solid tumors; T cell; T cell lineages; Vaccine |
| P160 | Engineering a T cell stimulating extra-cellular matrix for immunotherapy | John Hickey, BS; Yi Dong; Hai-Quan Mao, PhD; Jonathan P. Schneck, MD, PhD; | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma |
| P161 | The effects of IGF-1R antisense on cells of the glioma tumor microenvironment promotes immunostimulatory antigen release | Rhonda Kean, MS; Aurore LeBrun, PhD; Emily Bongiorno; David W. Andrews, MD; D. Craig Hooper, PhD; Samantha A. Garcia, PhD | Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Metabolism; Solid tumors; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| P162 | Single cell sequencing to identify TCRs that recognize autologous tumor cells after vaccination with allogeinic DRibble vaccine | Hong-Ming Hu, PhD; Christopher C. Paustian, PhD; Zhifa Wen; Tarsem L. Moudgil, MS; Traci L. Hilton, PhD; Sam Bookhardt, BA; Guangjie Yu; Eric Tran, PhD; Venkatesh Rajamanickam; Walter J. Urba, MD, PhD; Rachel E. Sanborn, MD; Bernard A. Fox, PhD | Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P163 | Humoral immune responses elicited by Globo H vaccine and the impact of Globo H expression levels on clinical response to Globo H vaccine in metastatic breast cancer | Jung-Tung Hung; I-Ju Chen; Wei-Chien Tang; Shir-Hwa Ueng; Tsai-Hsien Hung; Fei-Yun Lo; Hope Rugo, MD; Chiun-Sheng Huang; Alice L. Yu, MD, PhD | Antibody; Clinical trial; Immune monitoring; Solid tumors; Tumor antigens; Vaccine |
| P164 | Personalized cancer vaccines based on peptide-TLR-7/8a conjugates induce CD8 T cell responses to neoantigens in primates that are dependent on TLR-7/8a potency | Andrew S. Ishizuka, DPhil; Andrei Ramirez-Valdez; Hide Yamane, PhD; Yaling Zhu, PhD; Vincent Coble; Faezzah Baharom; Kennedy Tobin; Brennan Decker; Geoffrey Lynn; Robert A. Seder, MD | Bioinformatics; Immune adjuvant; Neoantigens; T cell; T cell lineages; TLR; Tumor antigens; Vaccine |
| P166 | Ex vivo ATLAS-identified inhibitory neoantigens promote mouse melanoma tumor progression | Hanna Starobinets, PhD; Kyle Ferber, PhD, BS; Jason R. Dobson, PhD, BS; Michael O'Keeffe; Crystal Cabral, BS, MSc; Matthew Lanchantin, BS; Erick Donis; Peri Matatia; Erik Carter; Adrienne Li, PhD; James Loizeaux; Jamie Foti, PhD; Wendy Broom, PhD; Pamela Carroll; Paul Kirschmeier; Jessica B. Flechtner, PhD; Hubert Lam, PhD; | Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Neoantigens; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor antigens |
| P167 | Characterization of antigen specific immune responses from a first-in-human study evaluating the anti-ASPH cancer vaccine SNS-301 in biochemically relapsed prostate cancer patients | Michael S. Lebowitz, PhD; Kanam Malhotra; M S. Walker; Hong Dai, MD, PhD; Steven Fuller, PhD; Amir Shahlaee, MD; James J. Elist, MD; Neal Shore, MD; Luke T. Nordquist, MD, FACP; Hossein A. Ghanbari, PhD | B cell; Clinical study; Immune tolerance; NK/NK T cell; Solid tumors; T cell; Tumor antigens |
| P168 | Induction of chemokine receptor and suppression of inhibitory receptors of CD8 T cell controlled effectively cervicovaginal tumor in mouse | Daewoo Lee, MD; Daeun Nam; Sungjong Lee, PhD, MD; | Chemokine; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P169 | In-Depth Characterization of Immune Responses Induced Against Patient-Specific Neoantigens using NEO-STIM™ | Brian McCarthy; Divya R. Lenkala; Michael Nelson; Rachel Debarge; Janani Sridar; Yusuf S. Nasrullah, Master's in Biological Research, United Kingdom; Jessica Kohler, PhD; Matthew J. Goldstein, MD, PhD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD; | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Dendritic cell; Neoantigens; T cell |
| P170 | Identification of breast cancer neoantigens exposed by radiation therapy | Claire Lhuillier, PhD; Nils-Petter Rudqvist, PhD; Takahiro Yamazaki, PhD; Tuo Zhang, PhD; Lorenzo Galluzzi, PhD; Sandra Demaria, MD | Neoantigens; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P171 | Safety and immunogenicity of a DNA vaccine encoding PSA and PSMA in patients with biochemically recurrent prostate cancer | Neal Shore, MD; Elisabeth Heath; Matthew P. Morrow, PhD; Kimberly Kraynyak, BS PhD; Kamal Bhatt, LCEH MS; Trevor McMullan; Jessica Lee, MS, MPH; Brian Sacchetta; Samantha Rosencranz; Ildiko Csiki, BS MD, PhD; Mark Bagarazzi, MD; Li Liu, PhD; | Clinical study; T cell; Vaccine |
| P172 | Personalized cancer vaccines based on self-assembling nanoparticles co-delivering peptide antigens and TLR-7/8 agonists (SNP-7/8a) enhance the breadth and magnitude of anticancer CD8 T cell immunity | Geoffrey Lynn; Faezzah Baharom; Yaling Zhu, PhD; Ramiro A. Ramirez-Valdez, BA Cantab; Tobin Kennedy; Vincent Coble; Brennan Decker; Hide Yamane, PhD; Andrew S. Ishizuka, DPhil; Robert A. Seder, MD | Immune adjuvant; T cell; Targeted therapy; TLR; Tumor antigens; Vaccine |
| P173 | Early results of a phase I clinical trial of a HER2 dendritic cell cancer vaccine | Hoyoung Maeng, MD; Lauren V. Wood, MD; Lee England, PA-C; Brenda Roberson, BSN, RN, OCN; Santhana Webb; Brittni Moore; David F. Stroncek, MD; John C. Morris, MD; Jay A. Berzofsky, MD, PhD; | Antigen presenting cells; Clinical trial; Dendritic cell; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P174 | A phase 1/2a study to evaluate the safety, tolerability, immunogenicity, and anti-tumor activity of GEN-009 adjuvanted neoantigen vaccine in adult patients with selected solid tumors | Roger Cohen; Michael S. Gordon, MD; Wendy Hill; Lisa K. McNeil, PhD; Tingting Ge, PhD; Arthur P. DeCillis, MD; Melissa L. Johnson, MD; Mark Awad, MD PhD; | Antigen presenting cells; Checkpoint blockade; Clinical study; Cytokine; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P175 | Targeting arginase in tumor microenvironment | Evelina Martinenaite, MSc; Shamaila Munir Ahmad; Simone Kloch Bendtsen, M.Sc; Mia Aaboe Jørgensen; Stine Emilie Weis-Banke; Inge Marie Svane, MD; Mads H. Andersen, PhD | Autoimmunity; Dendritic cell; Immune suppression; Immune tolerance; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P176 | Identification and analysis of critical immune molecules and signaling pathways to improve the immunogenicity of dendritic cell vaccines | Deena M. Maurer, MS; Patricia M. Santos, PhD; John M. Kirkwood, MD; Ahmad A. Tarhini, MD, PhD; Hussein A. Tawbi, MD, PhD; David F. Stroncek, MD; Ping Jin, PhD; Lisa H. Butterfield, PhD; | Antigen presenting cells; Checkpoint blockade; Costimulation; Dendritic cell; Metabolism; Targeted therapy; Vaccine |
| P177 | Boosting T cell immunity against IDO1: Proof of concept for a novel cancer vaccine approach | Alexander J. Muller, PhD; Souvik Dey, PhD; Erika Sutanto-Ward, BS; Katharina L. Kopp, BS; Mai-Britt Zocca, PhD; Ayako W. Pedersen, PhD; Mads H. Andersen, PhD | Immune contexture; Metabolism; T cell; T cell lineages; Tumor microenvironment; Vaccine |
| P178 | Identification of shared phosphopeptide tumor targets in colorectal carcinoma for novel off-the-shelf vaccine development | Paisley T. Myers, PhD; Erin D. Jeffery, PhD; Benjamin Morin, PhD; Christine Brittsan, MA; Bishnu Joshi; Antoine Tanne, PhD; Karen Smith, BS; Albert Hurwitz; Kara L. Cummings, PhD; Amanda M. Lulu; Daniel L. Levey, PhD; Linh Mach; Mark A. Findeis, PhD; Gayle C. Hunt, PhD; Jeffrey Shabanowitz, PhD; Donald F. Hunt, PhD; Arthur A. Hurwitz; Robert N. Stein, MD PhD; Alex Duncan, PhD; Dennis Underwood, PhD | Epidemiology; Neoantigens; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P179 | Use of Jurkat T cells for high throughput screening of chimeric antigen receptor constructs | Scott McComb, Ph.D; Risini D. Weeratna, PhD; Tina Nguyen, Ph.D. | CAR T cells; T cell |
| P180 | From infectious disease to personalized cancer vaccines: Integrated CD4, CD8, and regulatory T cell neo-epitope screening platform for the design of safe and customized vaccines | Guilhem Richard, PhD; Randy F. Sweis, MD; Leonard Moise, PhD; Matthew Ardito, BA; William Martin, BA MD; Gad Berdugo, MSc, MBA; Gary D. Steinberg, MD; Anne S. de Groot, MD | Antigen presenting cells; Bioinformatics; Biomarkers; Immune tolerance; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens |
| P181 | Pseudocowpox virus (PCPV), a potent tumor antigen-independent viral vector for cancer immunotherapy | Karola Rittner, PhD; Caroline Tosch, engineer; Thioudellet Christine; Christelle Remy-Ziller, Engineer; Marie-Christine Claudepierre, Ms; Benoit Sansas; Johann Foloppe; Philippe Erbs; Kaïdre Bendjama; Eric Quemeneur, PharmD, PhD; | Chemokine; Cytokine; Monocyte/Macrophage; Tumor antigens; Tumor microenvironment; Vaccine |
| P182 | Identification of prevalent immunogenic tumor antigens in microsatellite unstable patients with uterine corpus endometrial carcinoma. | Vladimir Roudko, PhD; Cansu Cimen Bozkus, PhD; Orfanelli Theofano, MD; Stephanie V. Blank, MD; Benjamin D. Greenbaum, PhD; Nina Bhardwaj, MD, PhD | Bioinformatics; Biomarkers; Neoantigens; Vaccine |
| P183 | Immunogenicity and specificity of neoantigens derived from tumor-specific mutations in gastric cancer | Tetsuro Sasada, MD, PhD; Junya Ohtake; Susumu Iizumi; Taku Kouro, MD, PhD; Yuka Igarashi; Mamoru Kawahara; Erika Yada | Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P184 | High tumour burden mandates a cancer vaccine targeting many neoantigens combined with check point inhibition | Elisa Scarselli, MD; Anna Morena D'Alise; Guido Leoni; Gabriella Cotugno; Fulvia Troise; Francesca Langone; Imma Fichera; Maria De Lucia; Rosa Vitale; Adriano Leuzzi; Veronica Bignone; Elena Di Matteo; Fabio Tucci; Lidia Avalle; Valeria Poli; Armin Lahm; Maria Teresa Catanese; Antonella Folgori; Stefano Colloca; Alfredo Nicosia; Elisa Scarselli | Checkpoint blockade; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P185 | CUE-101, a novel Fc fusion protein comprised of HLA-A*0201-bound HPV16 E7 peptide and IL-2, for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies | Mary C. Simcox, Ph.D.; Steven N. Quayle; Dharma R. Thapa, Ph.D.; Sandrine Hulot, Ph.D.; Alyssa Nelson, B.S.; Lauren Kraemer, B.S.; Zohra Merazga, M.S.; Robert Ruidera, MSc; Dominic Beal, Ph.D.; Gurpanna Saggu, Ph.D.; Maria Hackett, MSc; Mark Haydock, B.S.; Jonathan Soriano, MSc; Joey Lee; Luke Witt, B.S.; Kelly Malone; Jessica Ryabin, B.S.; Simon Low, MSc; Natasha Girgis, Ph.D.; Emily Spaulding, Ph.D.; John F. Ross, Ph.D.; Anish Suri, Ph.D.; Rodolfo Chaparro, Ph.D.; Ronald Seidel, Ph.D.; Kenneth J. Pienta, MD; | Costimulation; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P186 | A multi-center study of hTERT immunotherapy in adults with solid tumors at high risk of relapse post-standard therapy: updated results from complete patient set | Anthony F. Shields, MD PhD; Autumn J. McRee, MD; Jennifer Johnson, MD; Weijing Sun, MD, FACP; Ashish Chintakuntlawar, MBBS, PhD; Naseem Prostak, BS MS; Kimberly Kraynyak, BS PhD; Matthew P. Morrow, PhD; Jeffrey M. Skolnik, MD; Robert H. Vonderheide, MD, DPhil | Clinical study; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P187 | Preclinical evidence for the potency and tumor selective activation of a novel EpCAM-CD3 Protease-Triggered Immune Activator (ProTIA) T-cell bispecific therapeutic | Bee-Cheng Sim; Desiree Thayer; Fan Yang; Tillman Pearce, MD; Zach Lange; Ulrich Ernst, PhD; Volker Schellenberger | Antibody; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P188 | Patient’s autologous T cells recognize tumor specific neoantigens in PDX models of ovarian cancer | Muzamil Y. Want, PhD; Anna Konstorum, PhD; Ruea-Yea Huang, PhD; Richard C. Koya, MD, PhD; Sebastiano Battaglia, PhD | Adoptive immunotherapy; Bioinformatics; Neoantigens; T cell |
| P189 | A phase 1 study of safety and tolerability of AutoSynVax™ vaccine in patients with advanced cancer. | Robert Wesolowski, MD; Breelyn A. Wilky, MD; Allison O'Neill; Ana M. Gonzalez, MD PhD; Elise E. Drouin, PhD; Edward Dow; Mohamed Uduman; Antoine J. Tanne; Maria Agarwal, PhD; Bishnu Joshi; Benjamin Morin, PhD; Mark A. Findeis, PhD; Sandra Craig; Igor Proscurshim, MD; Ricardo Soto; Jennifer S. Buell, PhD; Robert N. Stein, MD PhD; John C. Castle; Daniel L. Levey, PhD | Clinical study; Solid tumors; Tumor antigens; Vaccine |
| P190 | Identification of antigenic epitopes of EGFR for lung cancer vaccine development | Juhua Zhou, PhD; Ge Guo; Jianzhong Zhang; Shaoyan Huang; Yanmin Li | Bioinformatics; Cytokine; Neoantigens; Solid tumors; Tumor antigens; Vaccine |
| O7 | The personal vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo tumor-related immunity in patients with advanced cancer | Siwen Hu-Lieskovan, MD, PhD; Ramaswamy Govindan, MD; Aung Naing, MD, FACP; Terence Friedlander, MD; Kim A. Margolin, MD; Jessica J. Lin, MD; Nina Bhardwaj, MD, PhD; Matthew Hellmann, MD; Lakshmi Srinivasan, Ph.D; Joel Greshock; Melissa Moles; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Patrick A. Ott, MD, PhD; | Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| O8 | The GAPVAC approach of actively personalized peptide vaccination for patients with newly diagnosed glioblastoma. | Norbert Hilf, PhD; Sabrina Kuttruff-Coqui, PhD; Katrin Frenzel; Valesca Bukur; Stefan Stevanovic; Cecile Gouttefangeas, PhD; Michael Platten, MD; Ghazaleh Tabatabai; Valérie Dutoit; Sjoerd H. van der Burg, PhD; Per Thor Straten; Francisco Martínez-Ricarte, MD; Berta Ponsati; Hideho Okada, MD, PhD; Ulrik Lassen; Arie Admon; Christian Ottensmeier, MD PhD FRCP; Alexander Ulges; Sebastian Kreiter, MD; Andreas von Deimling; Marco Skardelly; Denis Migliorini; Judith Kroep, MD, PhD; Manja Idorn, PhD; Jordi Rodon; Jordi Piro; Hans S. Poulsen; Bracha Shraibman; Katy McCann; Regina Mendrzyk; Martin Löwer; Monika Stieglbauer; Cedrik Britten, MD; David Capper; Marij JP. Welters; Juan Sahuquillo; Marie Stockhausen; Katharina Kiesel; Evelyna Derhovanessian; Elisa Rusch; Colette Song; Sandra Heesch; Claudia Wagner; Alexandra Kemmer-Brueck; Jörg Ludwig; John Castle; Oliver Schoor, PhD; Jens Fritsche, PhD; Miriam Meyer; Nina Pawlowski, PhD; Sonja Dorner; Franziska Hoffgaard; Bernhard BR. Rössler, Dipl. INg (FH), MBA; Dominik Maurer, PhD; Toni Weinschenk, PhD; Carsten Reinhardt, MD, PhD; Christoph Huber, MD; Hans-Georg Rammensee, PhD; Harpreet Singh, PhD; Ugur Sahin, MD; Pierre-Yves Dietrich; Wolfgang Wick, MD | Clinical trial; Immune adjuvant; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
